Page 2 - Phase 2 Study News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Shanghai Yingli Pharmaceuticals Ltd (Yingli Pharma), a clinical stage pharmaceutical company providing new therapies for cancer and metabolic diseases, announced today the topline data from a clinical trial sponsored by the company at the annual meeting of the European Hematology Association (EHA) being held June 9-17, 2021.

Brazil Phase 2 Pivotal clinical trial of COVI-MSC is now authorized to proceed.The study will compare therapy using mesenchymal stem cells to placebo (and standard of care) in 100 COVID-19 patients hospitalized due to acute respiratory distress syndrome (ARDS).Given the emergency status in Brazil, Sorrento has worked with ANVISA to obtain fast turn-around for the Phase 2 Pivotal clinical trial submission following positive Phase 1b results in the U.S.Maintaining an extreme sense of urgency, Sorrento anticipates commencing enrollment of patients in the study in June 2021. SAN DIEGO, May 20, 202...